CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lukaka@cato-chem.com
Candesartan Cilexetil

坎地沙坦酯 杂质对照品Candesartan Cilexetil Impurities

EP28 个杂质条目28 impurity entries

本页汇总 坎地沙坦酯 的 28 个杂质对照品条目,其中药典杂质标注了 EP/USP 编号。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 28 impurity reference standards of Candesartan Cilexetil with EP/USP numbering where applicable. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 坎地沙坦酯(Candesartan Cilexetil)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesA validated ultra high-pressure liquid chromatography method for separation of candesartan cilexetil impurities and its degradents in drug product
    Pharmaceutical methods · 2012 · Kumar ND et al.  ·  PMID 23781475  ·  DOI
  2. 杂质研究Impurity studiesSolid State Stability and Kinetics of Degradation for Candesartan-Pure Compound and Pharmaceutical Formulation
    Pharmaceutics · 2020 · Buda V et al.  ·  PMID 31972960  ·  DOI
  3. 杂质研究Impurity studiesStability-Indicating Liquid Chromatographic Methods with Photodiode Array Detection and Light Scattering Detection for Simultaneous Determination of Candesartan and Hydrochlorothiazide
    Journal of chromatographic science · 2018 · de Diego M et al.  ·  PMID 29236956  ·  DOI
  4. 分析方法Analytical MethodsDEVELOPMENT AND VALIDATION OF HPLC ANALYTICAL METHODS USED-FOR DETERMINATION OF ASSAY, CONTENT UNIFORMITY AND DISSOLUTION OF IMMEDIATE RELEASE CANDESARTAN CILEXETIL 32 MG TABLETS
    Acta poloniae pharmaceutica · 2017 · Yuce M, Capan Y  ·  PMID 29624240
  5. 分析方法Analytical MethodsDesign-Assisted Chemometric UV Spectrophotometric Determination of Candesartan Cilexetil, Chlorthalidone and Amlodipine Using Principal Component Regression, Partial Least Squares and Genetic Algorithm-Partial Least Squares Models
    Analytical science advances · 2026 · Amin KFM et al.  ·  PMID 42487652  ·  DOI

坎地沙坦酯 —— 原料药与杂质对照品Candesartan Cilexetil — drug substance & impurities

共 29 个条目(含原料药本体)29 items incl. the drug substance
Candesartan Cilexetil structure
EP原料药 APIAPI
坎地沙坦酯Candesartan Cilexetil
Candesartan Cilexetil
CAS No.145040-37-5
Chemical FormulaC33H34N6O6
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 1 (Candesartan Cilexetil EP Impurity A) structure
EPA
坎地沙坦酯杂质1 (坎地沙坦酯EP杂质A)Candesartan Cilexetil Impurity 1 (Candesartan Cilexetil EP Impurity A)
Candesartan Cilexetil Impurity 1 (Candesartan Cilexetil EP Impurity A)
CAS No.139481-58-6
Chemical FormulaC26H24N6O3
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 2(Candesartan Cilexetil EP Impurity B) structure
EPB
坎地沙坦酯杂质2(坎地沙坦酯EP杂质B)Candesartan Cilexetil Impurity 2(Candesartan Cilexetil EP Impurity B)
Candesartan Cilexetil Impurity 2(Candesartan Cilexetil EP Impurity B)
CAS No.869631-11-8
Chemical FormulaC31H30N6O6
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 3(Candesartan Cilexetil EP Impurity C) structure
EPC
坎地沙坦酯杂质3(坎地沙坦酯EP杂质C)Candesartan Cilexetil Impurity 3(Candesartan Cilexetil EP Impurity C)
Candesartan Cilexetil Impurity 3(Candesartan Cilexetil EP Impurity C)
CAS No.1185255-99-5
Chemical FormulaC33H34N6O6
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 4(Candesartan Cilexetil EP Impurity D) structure
EPD
坎地沙坦酯杂质4(坎地沙坦酯EP杂质D)Candesartan Cilexetil Impurity 4(Candesartan Cilexetil EP Impurity D)
Candesartan Cilexetil Impurity 4(Candesartan Cilexetil EP Impurity D)
CAS No.1185256-03-4
Chemical FormulaC33H34N6O6
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 5(Candesartan Cilexetil EP Impurity E) structure
EPE
坎地沙坦酯杂质5(坎地沙坦酯EP杂质E)Candesartan Cilexetil Impurity 5(Candesartan Cilexetil EP Impurity E)
Candesartan Cilexetil Impurity 5(Candesartan Cilexetil EP Impurity E)
CAS No.914613-35-7
Chemical FormulaC35H38N6O6
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 6 (Candesartan Cilexetil EP Impurity F) structure
EPF
坎地沙坦酯杂质6 (坎地沙坦酯EP杂质F)Candesartan Cilexetil Impurity 6 (Candesartan Cilexetil EP Impurity F)
Candesartan Cilexetil Impurity 6 (Candesartan Cilexetil EP Impurity F)
CAS No.914613-36-8
Chemical FormulaC35H38N6O6
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 7 (Candesartan Cilexetil EP Impurity G) structure
EPG
坎地沙坦酯杂质7 (坎地沙坦酯EP杂质G)Candesartan Cilexetil Impurity 7 (Candesartan Cilexetil EP Impurity G)
Candesartan Cilexetil Impurity 7 (Candesartan Cilexetil EP Impurity G)
CAS No.139481-59-7
Chemical FormulaC24H20N6O3
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 8(Candesartan Cilexetil EP Impurity H) structure
EPH
坎地沙坦酯杂质8(坎地沙坦酯EP杂质H)Candesartan Cilexetil Impurity 8(Candesartan Cilexetil EP Impurity H)
Candesartan Cilexetil Impurity 8(Candesartan Cilexetil EP Impurity H)
CAS No.170791-09-0
Chemical FormulaC52H48N6O6
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 9(Candesartan Cilexetil EP Impurity I) structure
EPI
坎地沙坦酯杂质9(坎地沙坦酯EP杂质I)Candesartan Cilexetil Impurity 9(Candesartan Cilexetil EP Impurity I)
Candesartan Cilexetil Impurity 9(Candesartan Cilexetil EP Impurity I)
CAS No.139481-69-9
Chemical FormulaC25H22N6O3
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 7-d4 (Candesartan Cilexetil EP Impurity G-d4) structure
EPG-D4
坎地沙坦酯杂质7-d4 (坎地沙坦酯EP杂质G-d4)Candesartan Cilexetil Impurity 7-d4 (Candesartan Cilexetil EP Impurity G-d4)
Candesartan Cilexetil Impurity 7-d4 (Candesartan Cilexetil EP Impurity G-d4)
CAS No.1346604-70-3
Chemical FormulaC24H16D4N6O3
Purity>95%询价On request
Candesartan Cilexetil Impurity 7-d5 (Candesartan Cilexetil EP Impurity G-d5) structure
EPG-D5
坎地沙坦酯杂质7-d5 (坎地沙坦酯EP杂质G-d5)Candesartan Cilexetil Impurity 7-d5 (Candesartan Cilexetil EP Impurity G-d5)
Candesartan Cilexetil Impurity 7-d5 (Candesartan Cilexetil EP Impurity G-d5)
CAS No.1189650-58-5
Chemical FormulaC24H15D5N6O3
Purity>95%询价On request
Candesartan Cilexetil Impurity 10 structure
10
坎地沙坦酯杂质10Candesartan Cilexetil Impurity 10
Candesartan Cilexetil Impurity 10
CAS No.1026042-12-5
Chemical FormulaC32H32N6O6
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 11 structure
11
坎地沙坦酯杂质11Candesartan Cilexetil Impurity 11
Candesartan Cilexetil Impurity 11
CAS No.168434-02-4
Chemical FormulaC22H16N6O3
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 12 structure
12
坎地沙坦酯杂质12Candesartan Cilexetil Impurity 12
Candesartan Cilexetil Impurity 12
CAS No.1203674-06-9
Chemical FormulaC23H18N6O3
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 13 structure
13
坎地沙坦酯杂质13Candesartan Cilexetil Impurity 13
Candesartan Cilexetil Impurity 13
CAS No.1225044-20-1
Chemical FormulaC24H20N6O3
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 14 structure
14
坎地沙坦酯杂质14Candesartan Cilexetil Impurity 14
Candesartan Cilexetil Impurity 14
CAS No.139481-72-4
Chemical FormulaC43H34N6O3
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 15 structure
15
坎地沙坦酯杂质15Candesartan Cilexetil Impurity 15
Candesartan Cilexetil Impurity 15
CAS No.856414-35-2
Chemical FormulaC45H38N6O3
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 17 structure
17
坎地沙坦酯杂质17Candesartan Cilexetil Impurity 17
Candesartan Cilexetil Impurity 17
CAS No.1265625-66-8
Chemical FormulaC21H18N6O2
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 18 structure
18
坎地沙坦酯杂质18Candesartan Cilexetil Impurity 18
Candesartan Cilexetil Impurity 18
CAS No.886999-34-4
Chemical FormulaC52H48N6O6
Purity>95%现货In stock
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 21 structure
21
坎地沙坦酯杂质21Candesartan Cilexetil Impurity 21
Candesartan Cilexetil Impurity 21
CAS No.139481-28-0
Chemical FormulaC22H17N3O4
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 26 structure
26
坎地沙坦酯杂质26Candesartan Cilexetil Impurity 26
Candesartan Cilexetil Impurity 26
CAS No.1799484-55-1
Chemical FormulaC30H32N6O5·2HCl
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 27 structure
27
坎地沙坦酯杂质27Candesartan Cilexetil Impurity 27
Candesartan Cilexetil Impurity 27
CAS No.1867269-67-7
Chemical FormulaC35H40N6O7
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 28 structure
28
坎地沙坦酯杂质28Candesartan Cilexetil Impurity 28
Candesartan Cilexetil Impurity 28
CAS No.1246819-02-2
Chemical FormulaC26H24N6O3
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 29 structure
29
坎地沙坦酯杂质29Candesartan Cilexetil Impurity 29
Candesartan Cilexetil Impurity 29
CAS No.1246817-38-8
Chemical FormulaC26H24N6O3
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 31 structure
31
坎地沙坦酯杂质31Candesartan Cilexetil Impurity 31
Candesartan Cilexetil Impurity 31
CAS No.1821385-89-0
Chemical FormulaC33H32N6O6
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 32 structure
32
坎地沙坦酯杂质32Candesartan Cilexetil Impurity 32
Candesartan Cilexetil Impurity 32
CAS No.1821386-35-9
Chemical FormulaC24H18N6O3
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 34 structure
34
坎地沙坦酯杂质34Candesartan Cilexetil Impurity 34
Candesartan Cilexetil Impurity 34
CAS No.99464-83-2
Chemical FormulaC9H15ClO3
Purity>95%询价On request
10mg25mg50mg100mg
Candesartan Cilexetil Impurity 35 structure
35
坎地沙坦酯杂质35Candesartan Cilexetil Impurity 35
Candesartan Cilexetil Impurity 35
CAS No.2248319-77-7
Chemical FormulaC12H14N2O6
Purity>95%询价On request
10mg25mg50mg100mg

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

坎地沙坦酯 —— 研究文献与合成路线Candesartan Cilexetil — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 坎地沙坦酯 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Candesartan Cilexetil. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. A validated ultra high-pressure liquid chromatography method for separation of candesartan cilexetil impurities and its degradents in drug product
    Kumar ND, Babu KS, Gosada U, et al. · Pharmaceutical methods · 2012 · 被引 3cited 3
  2. LC and LC-MS/TOF studies on stress degradation behaviour of candesartan cilexetil
    Mehta S, Shah RP, Priyadarshi R, et al. · Journal of pharmaceutical and biomedical analysis · 2010 · 被引 19cited 19
  3. Investigation and structural elucidation of a process related impurity in candesartan cilexetil by LC/ESI-ITMS and NMR
    Raman B, Sharma BA, Mahale G, et al. · Journal of pharmaceutical and biomedical analysis · 2011 · 被引 6cited 6
  4. PROCESS FOR PREPARATION OF CANDESART AN CILEXETIL SUBSTANTIALLY FREE OF DES-CANDESARTAN CILEXETIL IMPURITY
    PARTHASARADHI REDDY BANDI, RATHNAKAR REDDY DASARI, MURALIDHARA REDDY DASARI, et al. · 2011
  5. Validated spectrofluorimetric determination of two pharmaceutical antihypertensive mixtures containing amlodipine besylate together with either candesartan cilexetil or telmisartan
    Belal TS, Mahrous MS, Abdel-Khalek MM, et al. · Luminescence : the journal of biological and chemical luminescence · 2014 · 被引 19cited 19
  6. DEVELOPMENT AND VALIDATION OF HPLC ANALYTICAL METHODS USED-FOR DETERMINATION OF ASSAY, CONTENT UNIFORMITY AND DISSOLUTION OF IMMEDIATE RELEASE CANDESARTAN CILEXETIL 32 MG TABLETS
    Yuce M, Capan Y · Acta poloniae pharmaceutica · 2017 · 被引 1cited 1

合成与制备工艺专利Synthesis & process patents

  1. PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL
    ZUPANCIC SILVO · 公开号 US2012029201US2012029201 · 2012
  2. PROCESS FOR PREPARATION OF CANDESARTAN CILEXETIL
    MORI HIROYUKI, KOBAYASHI KENSUKE · 公开号 WO2011155291WO2011155291 · 2011
  3. PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL
    SINGH KAPTAN, SANJEEVI LAKSHMIPATHI V, SHIRSATH KRISHNARAO TUKARAM, ARORA SANJEEV KUMAR, et al. · 公开号 WO2011080684WO2011080684 · 2011
  4. Process for the Preparation of Candesartan Cilexetil
    ZUPANCIC SILVO · 公开号 US2010197933US2010197933 · 2010
  5. PROCESS FOR THE PREPARATION OF CANDESARTAN CILEXETIL
    DEO KESHAV, DESAI SANJAY, RATHOD DHIRAJ MOHANSINH, KATARIYA LALITKUMAR KESHAVIAL, et al. · 公开号 US2010210852US2010210852 · 2010

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

坎地沙坦酯 杂质谱研究要点Candesartan Cilexetil — impurity profiling notes

下面这些是拿到 坎地沙坦酯 的 29 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 29 impurity entries for Candesartan Cilexetil, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

本品种含药典编号杂质(EP/USP)。申报时药典已收载的杂质通常需要逐项对照,建议优先备齐药典编号对照品,再补充工艺与降解杂质。This drug substance includes pharmacopoeially designated impurities (EP/USP). Monographed impurities normally need item-by-item comparison during filing, so secure the pharmacopoeial standards first, then fill in process and degradation impurities.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances